RxDoctor Payments Data

Luis Gomez, MD

Vascular Surgery · Mishawaka, INNPI 1538570460

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $39,505 of the $52,050 with a category attached, or 75.9%. Endologix LLC accounts for 89.5% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $29,273, more than ten times the $304 reported in 2021. Among vascular surgery clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$52,050in general payments, 2019–2025

Across 155 payments — averaging $335.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endologix LLC$47K
  • Penumbra, Inc.$3K
  • W. L. Gore & Associates, Inc.$577
  • Cardiovascular Systems Inc.$304
  • Terumo Medical Corporation$285
  • Lemaitre Vascular, Inc.$243
  • plus $1K from 23 others

What the payments were for

  • Consulting fees$39,50576%
  • Travel & lodging$4,3008%
  • Food & beverage$8,01715%
  • Education$2290%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,050 in reported general payments places this provider in the 90th percentile of 71 vascular surgery providers in Indiana.

See all vascular surgery providers in Indiana

Medicare billing

Part B allowed, 2024
$105,892
Medicare patients
214
Services billed
579

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban23$20,257
ClopidogrelClopidogrel Bisulfate351$3,300
Atorvastatin Calcium246$1,773
Rosuvastatin Calcium49$457
Pregabalin13$338
Cilostazol12$254
Gabapentin26$198
Acetaminophen-CodeineAcetaminophen With Codeine24$122
Prednisone17$24

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$20,25723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 71 vascular surgery providers in Indiana.

Other vascular surgery in Mishawaka

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →